Royalty Report: Drugs, Antibody, Cancer – Collection: 344586

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Antibody
  • Cancer
  • Drug Discovery
  • Disease
  • Cell Line
  • DNA
  • Pain
  • Biotechnology
  • Therapeutic
  • Agriculture Forestry & Fishing
  • Crop Production
  • Vaccine
  • Proteins
  • Arthritis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 344586

License Grant
Licensor of England grants a worldwide non-exclusive license to use the System, the Cell Lines, the Materials, and the Intellectual Property to develop, manufacture, offer for sale, import, market and sell Product.
License Property
Product means the chimeric monoclonal antibody that binds to the phospholipid phosphatidylserine, known as TarvacinTM, of which antibody Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the Materials.

TarvacinTM is an Anti-Phospholipid Therapy agent.

Materials means the System and the Vectors, but excluding any gene proprietary to Licensee inserted into the System for the purposes of producing Product.

System means the glutamine synthetase gene expression system of which Licensor is the proprietor, as the same is described in the Intellectual Property.

Vectors means those vectors containing the System.

The patents are titled
Transformed Myeloma Cell-Line and a Process for the Expression of a Gene Coding for a Eukaryotic Polypeptide employing same;
Recombinant DNA Sequences, Vectors containing them and Method for the use thereof;
Recombinant DNA Product and Processes using it; and,
Recombinant DNA Methods, Vectors and Host Cells.

Field of Use
Tarvacinâ„¢, a novel anti-cancer agent.  Tarvacinâ„¢ is part of Peregrine's Anti-Phospholipid Therapy (APT) platform, which binds directly to tumor blood vessels to inhibit tumor growth and development. Tarvacinâ„¢ is a chimeric monoclonal antibody that binds to the phospholipid, phosphatidylserine.

IPSCIO Record ID: 344585

License Grant
Licensor of England grants a worldwide non-exclusive license to use the System, the Cell Lines, the Materials, and the Intellectual Property to develop, manufacture, market and sell Product.
License Property
Licensor is the proprietor of a system for gene expression utilizing glutamine synthetase.

The patents are titled
Transformed Myeloma Cell-Line and a Process for the Expression of a Gene Coding for a Eukaryotic Polypeptide employing same;
Recombinant DNA Sequences, Vectors containing them and Method for the use thereof;
Recombinant DNA Product and Processes using it , and,
Recombinant DNA Methods, Vectors and Host Cells.

Product means DNA/histone directed antibody of human or chimeric origin, in combination with radio isotope or another component, of which antibody Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the Materials.

System means the glutamine synthetase gene expression system of which Licensor is the proprietor, as the same is described in the Intellectual Property.

Field of Use
The Licensee has been engaged in the development of drugs and related therapies for the treatment of people with cancer.

IPSCIO Record ID: 239013

License Grant
The English Licensor hereby grants to Licensee a world-wide non-exclusive licence under the Intellectual Property to develop, manufacture, market and sell Product in the Territory, there shall be no right to sublicense the rights granted hereunder.
License Property
US Patents Rights
5,981,216 – Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
5,770,359 – Recombinant DNA sequences, vectors containing them and method for the use thereof
5,827,739 – Recombinant DNA sequences, vectors containing them and method for the use thereof
5,591,639 – Recombinant DNA expression vectors
5,658,759 – Recombinant DNA expression vectors

Product means a monoclonal antibody to a bacterial cell surface adhesion known as Aurexis(TM) of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the Materials, or any formulation containing the same.

Intellectual property and materials relating to the expression of recombinant monoclonal antibodies to bacterial surface proteins for use in the manufacture of Aurexis.

Field of Use
Aurexis is currently being evaluated in a Phase II clinical trial as a first-line therapy, in combination with standard of care antibiotics, to treat serious, life-threatening Staphylococcus aureus, or S. aureus, bloodstream infections in hospitalized patients.

IPSCIO Record ID: 260399

License Grant
Swiss Licensor hereby grants to Australian Licensee a world-wide non-exclusive license (with the right to sublicense) under the System Know-How and Patent Rights to use, develop, manufacture, market, sell, offer for sale, distribute, import and export Product in the Territory.
License Property
System means Licensor’s glutamine synthetase gene expression system consisting of the Cell Lines, the Vectors, and the System Know-How, whether used individually or in combination with each other. For the avoidance of doubt, any gene proprietary to Licensee inserted into the System for the purposes of producing Product does not form part of the System.

Product means the caninised IgG-A kappa antibody produced by the Cell Line known as NV-01 that binds to NGF and of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the System, or any formulation containing the same. Combination Product means any diagnostic or therapeutic product comprising Product and one or more other pharmaceutical active ingredient(s).

NV-01 is a mAb that is a nerve growth factor, or NGF, inhibitor for the control of pain associated with osteoarthritis in dogs

Cell Lines Two 1.5 ml vials of myeloma cell line NSO.
Two 1.5 ml vials of the Chinese Hamster Ovary cell line CHO-K1sv

Vectors Approximately 20µg of vector pEE12.4.
Approximately 20i1g of vector pEE6.4.

Patent Rights means the patents and applications.
5,981,216 – Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
5,591,639 – Recombinant DNA expression vectors
5,879,936 – Recombinant DNA methods, vectors and host cells

Field of Use
Field of use is for the control of pain associated with osteoarthritis in dogs.  Osteoarthritis (OA) is the most common form of arthritis.

IPSCIO Record ID: 369334

License Grant
Licensor of England grants a world-wide non-exclusive license under the Intellectual Property to exploit the System make, have made, use, develop, manufacture, market, sell, have sold, offer for sale, distribute, import, and export Product in the Territory.
License Property
The Product means a humanized monoclonal antibody known as Sphingomabâ„¢, which targets sphingosine-1-phosphate (S1P), or an S1P-binding fragment thereof, of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the System.

The System means Licensors glutamine synthetase gene expression system consisting of the Cell Lines, the Vectors, and the System Know-How, whether used individually or in combination with each other.

Field of Use
Licensee has announced the humanization of its Sphingomabâ„¢ monoclonal antibody against sphingosine-1-phosphate (S1P). S1P is an important bioactive lipid that has been well validated as a cancer drug target.

IPSCIO Record ID: 28254

License Grant
The Swiss Licensor grants to Licensee a world-wide non-exclusive licence, with the right to sublicense, under the System Know-How and Patent Rights to use, develop, manufacture, market, sell, offer for sale, distribute, import and export momoclonial antibody Product in the Territory.
License Property
“Product” means the GS-CHOK1SV-derived monoclonal antibody PRO 140, of which Licensee is the proprietor, obtained by the expression of any one gene or of any combination of genes by use of the System, or any formulation containing the same.

System means the Licensor's glutamine synthetase gene expression system consisting of the Cell Lines, the Vectors, and the System Know-How, whether used individually or in combination.

Subject Matter Expression of polypeptides, such as antibodies, in myeloma cell lines
Title Transformed Myeloma Cell-Line and a Process for the Expression of a Gene Coding for a Eukaryotic Polypeptide Employing Same

Subject Matter GS Coding sequence
Title Recombinant DNA which encodes glutamine synthetase

Subject Matter Expression systems containing a hCMV promoter
Title Recombinant DNA Expression Vectors

Subject Matter Operation of glutamine synthetase expression systems in lymphoid cells
Title Recombinant DNA Methods, Vectors and Host Cells

USA (cont I) 12.06.92 5879936 09.03.16
USA (cont II) 23.01.95 5891693 06.04.16

Field of Use
The Licensee wishes to commercially exploit the Product. Product means the GS-CHOK1SV-derived monoclonal antibody PRO 140, of which Licensee is the proprietor, obtained by the expression of any one gene or of any combination of genes by use of the System, or any formulation containing the same.

The Licensee will use the PRO 140 monoclonal antibody for treatment of HIV, after a recent study found that it suppressed the HIV virus in patients.

IPSCIO Record ID: 240466

License Grant
The Licensor of England grants to the Licensee the following licenses under the Winter Patent
– a non-exclusive world-wide license to exploit the Winter Patent commercially in any way whatsoever by the use of the Reshaping Process in the Fields and by the commercial exploitation in the Fields of any resulting antibodies provided always that any such exploitation does not involve the antibodies detailed.
– a non-exclusive sub-license under the Boss Patents to the extent required to enable the licensee to use the Reshaping Process to produce Products from mammalian cells and for no other purpose.
License Property
Licensor has certain patent rights in respect of the genetic engineering of monoclonal antibodies comprising the replacement in whole or in part of the complementarity determining regions of one antibody by those of another.

The Reshaping Process shall mean the genetic engineering of monoclonal antibodies comprising the replacement in whole or in part of the complementarity determining regions of one antibody by those of another as described in the Winter Patent.

The Products shall mean end products produced either directly or indirectly from antibodies which have been modified using the Reshaping Process and which are in a form capable of being marketed or sold upon a commercial basis.

Winter patents relate to Recombinant DNA products and Methods.

Boss patents relate to Multichain Polypeptides or Proteins and Processes for their Production Expression of multichain proteins, such as antibodies, in single hose cells.

Field of Use
The Fields shall mean the field of human therapy or prophylaxis and human in vivo and in vitro diagnostics.

IPSCIO Record ID: 280819

License Grant
For the Research the German Licensor grants a non-exclusive research license under Licensor Background Inventions and Licensors rights in Collaboration Data, Collaboration Materials and Collaboration Inventions, to perform its obligations under the Collaboration Plan.

For the Commercial License,  Licensor grants an exclusive, worldwide license to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products for use in the Field directed to such Licensee Target under Licensor Background Inventions, and under Licensors rights in all Patent Rights and Collaboration Inventions and Collaboration Material pertaining to such Licensee Target and Licensed Products, or the uses thereof in the Field.

License Property
Licensors HuCAL Technologies shall mean the HuCAL library and associated technologies.   The library data is for a Design of Human Combinatorial Antibody Library-Fab (HuCAL-Fab).
Field of Use
The field shall mean all therapeutic indications.  With this agreement, the Parties will collaborate in the discovery and development of human monoclonal antibodies against certain specified Licensee Targets,  to generate and characterize antibodies and optimize those antibodies and  use their expertise in developing antibodies in pre-clinical and clinical settings.

The two companies will collaborate on the development of human antibodies for the treatment of cancer.

IPSCIO Record ID: 256278

License Grant
On the Effective Date the Parties have terminated a certain Collaboration Agreement, and with this agreement, the Parties desire to reallocate the rights and responsibilities of the Parties with respect to further research and development of the GM-CSF Target.

Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.

Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.

License Property
BiTE Product means any composition or formulation consisting of or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells.

GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.

Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.

Field of Use
The field for Patent 5,223,409 is solely in the field of manufacture, use or sale of Single Chain Antibodies.

The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.

Products for Radioimmunoguided SurgeryTM (RIGS'), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody.

IPSCIO Record ID: 202855

License Grant
Licensor grants to Licensee under all Licensors Patents a nonexclusive, worldwide, sublicensable license to the extent necessary to make, have made, use, sell, have sold and import Licensees Licensed Products for the treatment, prophylaxis or diagnosis of any disease or condition in humans and animals; provided, however, that with respect to Licensees Licensed Products containing an Anti-IgE Antibody identified and synthesized before June 1, 1997, and/or Licensors Patents issued before June 1, 1999, the foregoing limitation -to the extent necessary- shall not be applicable.
License Property
Anti-IgE Antibody means an antibody directed against the immunoglobulin IgE as an antigen, fragments or conjugates of such antibodies, and other constructs comprising antibodies which are derived from or contain any of the above-specified components.

Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.

Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.

Field of Use
The agreement is for antibodies for immunology, infectious diseases and cancer.

IPSCIO Record ID: 243460

License Grant
The Irish Licensor grants to the Licensee of England a worldwide, non-exclusive, non-transferable license, solely on its own behalf and on behalf of any Licensee Collaborator, without any right to sublicense, under the Licensor Patent Rights to
(a) Make or have made Licensed Antibody Phage Display Materials;
(b) Solely for Research and Development purposes, conduct Antibody Phage Display;
(c) Make or have made Research Quantities of a Licensed Immunoglobulin;
(d) Transfer Antibody Phage Display Materials, Research Quantities of a Licensed Immunoglobulin or Licensed Immunoglobulin Information to a Licensee Collaborator; and
( e) Use, sell, offer to sell, import and export Licensed Immunoglobulins.
License Property
The patents include Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use, and, Modular Assembly of Antibody Genes, Antibodies, and, Novel Plasmid Vector with Pectate Lyase Signal Sequence.

Antibody Phage Display means the authorized use of Licensed Antibody Phage Display Materials to conduct Research and Development.

Licensed Antibody Phage Display Materials means any collection or library of polynucleotide sequences, including without limitation a Licensee Library, created by Licensee and under the exclusive control of Licensee, which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or any collection or library of bacteriophage, including without limitation a Licensee Library, created by or under the exclusive control of Licensee, wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin and an outer surface polypeptide of a bacteriophage.

Licensed Immunoglobulin means any Immunoglobulin discovered, isolated or characterized by Licensee or a Licensee Collaborator through the use of Licensed Antibody Phage Display Materials.

Field of Use
The field is antibody drug discovery.

IPSCIO Record ID: 56588

License Grant
In this related party agreement, the Licensor hereby grants to Licensee a nonexclusive license in the Territory, with the right to sublicense, to use iBioLaunchâ„¢ Technology and iBio Additional Technology to conduct Process Development, Scale-Up, and R&D activities on Pharmaceutical Products in the Territory. Additionally, subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a nonexclusive license in the Territory, with the right to sublicense, to use the iBio Additional Technology to conduct Process Development, Scale-Up, and R&D activities on Products in the Territory.
License Property
The patents and technology are for the accelerated discovery and production of improved vaccines, monoclonal antibodies, therapeutic proteins, and other products derived from green plants utilizing its iBioLaunchâ„¢ plant-based platform technology and other proprietary technologies.

7,012,172   VIRUS INDUCED GENE SILENCING IN PLANTS   3/14/2006
          
7,491,509   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   2/17/2009
          
7,683,238   PRODUCTION OF PHARMACEUTICALLY ACTIVE PROTEINS IN SPROUTED SEEDLINGS   3/23/2010
          
7,692,063   PRODUCTION OF FOREIGN NUCLEIC ACIDS AND POLYPEPTIDES IN SPROUT SYSTEMS   4/6/2010
          
8,058,511   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   11/15/2011
          
8,148,608   SYSTEMS AND METHODS FOR CLONAL EXPRESSION IN PLANTS   4/3/2012
          
8,173,408   RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES   5/8/2012
          
8,591,909   RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES   11/26/2013
          
8,597,942   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   12/3/2013
          
8,951,791   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   2/10/2015
          
9,012,199   RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES   4/21/2015

Field of Use
This agreement pertains to the patents and technologies for research, process development and scale-up, and manufacturing of plant-derived products in a manufacturing facility designed for that purpose relating to drugs in the healthcare industry.

IPSCIO Record ID: 294014

License Grant
Licensor, a medical research centers, grants an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
The patents and patent applications relate to Modified Adena-Associated Virus Vector Capable of Expression from a Novel Promoter.

Adeno-associated viruses are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae.

Field of Use
The field of use is the development of compositions and methods utilizing Adeno-Associated Viral Vectors embodied in the Licensed Patent Rights which are useful in the treatment and prophylaxis of human and animal diseases, and does not include compositions and methods for the treatment and prophylaxis of cystic fibrosis.

Cystic fibrosis is a hereditary disease that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. Cystic fibrosis (CF) can be life-threatening, and people with the condition tend to have a shorter-than-normal life span.

IPSCIO Record ID: 121012

License Grant
Pursuant to this Settlement and Cross-license agreement, Licensor grants to Licensee of Bermuda under all Licensor Patents, on a country-by-country basis in the Licensees Territory, an exclusive, sublicenseable license to make, have made, use, sell, have sold and import Licensees Licensed Products for the treatment, prophylaxis or diagnosis of any disease or condition in humans;  with respect to Licensees Licensed Products containing an Anti-IgE Antibody identified and synthesized before June 1, 1997, and/or Licensors Patents issued before June 1, 1999.
License Property
Anti-IgE Antibody means an antibody directed against the immunoglobulin IgE as an antigen, fragments or conjugates of such antibodies, and other constructs comprising antibodies which are derived from or contain any of the above-specified components.

Licensees Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody.

Licensors Licensed Product means any pharmaceutical formulation or product or method or system which contains an Anti-IgE Antibody identified and synthesized by Licensor and/or a third party, or other IgE inhibiting antibodies within Licensorss MIGIS(R) program.

Field of Use
The agreement is for the drug industry relating to antibodies for immunology, infectious diseases and cancer.

IPSCIO Record ID: 372444

License Grant
The existing agreement is for the rights to use Licensor’s antibody phage display technology.  This agreement is to extend the term  and amend other terms.

Licensee shall have rights to use and practice the Licensor Technology, and Licensor licensed Patent Rights and Know-How as follows
— For the Licensor Antibody library, Licensor grants to Licensee a world-wide, nonexclusive license, without the right to grant sublicenses, to use the Licensor Antibody Library and to practice the Licensor Patent Rights solely in connection with the use of the Licensor Antibody Library to research, develop and make Antibody Compounds and a world-wide, nonexclusive license, with the right to sublicense, to use the Antibody Compounds in order to make, have made, use, sell or import Licensed Products.

For Licensor Materials, In connection with the practice of the license rights set forth, Licensor grants to Licensee a worldwide, non-exclusive, non-transferable license, without the right to grant sublicenses, to use the Licensor Materials on its own behalf only to identify Antibody Compounds from the Licensor Antibody Library and to make quantities of Antibody Compounds that are reasonably required for research and development activities only.

For the Third Party Sublicense Rights, During the library License Term, Licensee shall have rights to use and practice the Licensor licensed Patent Rights and Know-How.

License Property
Licensor possesses intellectual property and know-how related to, among other things, the discovery of antibodies having novel binding properties using phage display.

Licensed Product means any Antibody Compound or product that incorporates an Antibody Compound, whether or not conjugated to another compound that is a Therapeutic Product or an In Vitro Diagnostic Product.

The licensed library is The phagemid-based Fab library.

Licensed materials include Expression vectors pXPlsacB and pXP2sacB for soluble Fab production in E. coli. IgG expression vectors (pBRV and pShuttle) for rapid subclomng and converting Fab fragments into human IgGl and IgG4 and munne IgG2a. (Streptavidin-binding antibody clones will be provided as a positive control.)

The patents include
— Phage display patents
— Focused libraries of genetic packages
— Novel methods of constricting libraries of human FAB antibody fragments displayed on filamentous phage
— Ligand Screening and Discovery
— Modular Assembly of Antibody Genes, Antibodies Prepared Thereby and Use
— Novel Plasmid Vector with Pectate Lyase Signal Sequence

Field of Use
The field of use is Therapeutic Field of Use means shall mean human therapeutics only and not for any in vitro or in vivo diagnostics, purification or separations, research products nor for any other purposes.

IPSCIO Record ID: 279345

License Grant
The English Licensor hereby grants to the English Licensee (i) a non-exclusive worldwide sublicense, with the right to grant further Sublicenses, under the Licensed Patent Rights to make, have made, use, import, offer for sale, and/or sell Licensed Products; and (ii) an exclusive worldwide license, with the right to grant Sublicenses, under the Licensor IP to make, have made, use, import, offer for sale, and/or sell Licensed Products.
License Property
US Patent #5,225,539 – Recombinant altered antibodies and methods of making altered antibodies

Licensed Product shall mean a product comprising a Humanized Antibody, the manufacture, use, offer for sale, sale, or importation of which by an unlicensed third party would infringe one or more Valid Claims of the Licensed Patent Rights, or which incorporates Licensor IP or Licensor Inventions.  The term “Licensed Product” does not include chimeric antibodies or murine antibodies.

Humanized Antibody shall mean an antibody that binds to Sphingosine-1-phosphate and is made by Licensor under this Agreement, the antibody comprising murine complementarity determining regions derived from Sphingomabâ„¢ together with human framework regions, and any modifications thereof.

Licensor IP shall mean (i) any Licensor Invention and (ii) all patented and non-patented proprietary technology and information, in any form whatsoever, that is (a) necessary or useful for making and using the Licensed Products, without regard to whether or not the technology or information is patentable; (b) owned, controlled, or developed by Licensor, as of the Effective Date or hereafter during the term of this Agreement; and (c) provided by Licensor to Licensee hereunder, including, but not limited to discoveries, formulae, materials, practices, methods, knowledge, know-how, processes, trade secrets, ideas, concepts, manufacturing, engineering, standard operating procedures, flow diagrams and charts, quality assurance, quality control data, technical data, manufacturing technology, research data and records, and all other confidential or proprietary technical and business information relating to the humanization of murine antibodies, generation of chimeric antibodies, or any gene expression vectors used in such methods and all improvements or modifications thereto.  For purposes of clarity, Licensor IP includes Licensor Inventions that satisfy (a), (b) and (c), above, while Licensor IP does not include Licensed Patent Rights as defined hereunder.

Licensor Invention shall mean any discovery or invention to the extent (i) made or conceived or reduced to practice by or on behalf of Licensor in the performance of the humanization of Licensees Sphingomabâ„¢ antibody under this Agreement, whether or not patentable, and (ii) covering only generally applicable methods or techniques for humanizing antibody proteins or for constructing a vector or reagent used to humanize or express an antibody.

Field of Use
Licensee’s lead product candidate, Sphingomab™, is a monoclonal antibody (mAb) against sphingosine-1-phosphate (S1P), an innovative and validated cancer target.

Sphingomabâ„¢ is the original mouse version of this monoclonal antibody.

IPSCIO Record ID: 256276

License Grant
The Licensor of England grants to Licensee of Germany a nonexclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to Exploit Licensed Products in the Field.
License Property
Licensor is a UK-based biotechnology company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development.

Licensed Product means any product, substance or formulation arising from the Target Program, and the Development, manufacture, importation, use or sale of which would but for the provisions of this Agreement infringe one or more Valid Claims under the Licensor Licensed Patents, or which utilizes the Licensor Background Know-How.

The know-how includes Training Manual Antibody Phage Display 2002, and, mammalian expression IgG vectors.

Field of Use
The Field means the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the Target. Target means the whole or part and natural variants of the granulocyte-macrophage colony stimulating factor (GM-CSF) identified by the SWISS-PROT entry name CSF2_HUMAN and accession number P04141 with the amino acid sequence which is specifically recognized by an Antibody binding to the foregoing.

Licensee obtains the right within the framework of their collaboration to use Licensor’s intellectual property in phage display to create and commercialise novel antibody products against a defined number of targets.

IPSCIO Record ID: 260403

License Grant
The Swiss Licensor hereby grants to Australia Licensee
(a)
a world-wide non-exclusive license under the System Know-How, CDACF Version 8 Know-How, and the Patent Rights Licensor) (with the right to sublicense);
(b)
a world-wide non-exclusive sublicense under the Patent Rights (Third Party) (with the right to sublicense);
in each case (a) and (b) to use, develop, manufacture, market, sell, offer for sale, distribute, import and export Product in the Territory (Commercial Activities).
License Property
Product means the felinised IgG kappa antibody produced by the Cell Line known as NV-02 that binds to NGF and of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the System, or any formulation containing the same.

NV-02, is a mAb that is an NGF inhibitor for the control of pain associated with degenerative joint disease in cats.

Cell Lines means Two 1.5 ml vials of the CHOK1SV-GS-KO cell line.
Vectors means Approximately 20ug of vector pXC-17.4 and approximately 20ug of vector pXC-18.4

System means Licensor’s glutamine synthetase gene expression system known as GS Xceed™ consisting of the Cell Lines and the Vectors, and the System Know-How, whether used individually or in combination with each other. For the avoidance of doubt, any gene proprietary to Licensee inserted into the System for the purposes of producing Product does not form part of the System.

CDACF Version 8 Base Powders means the powders listed
CHO
• Licensor medium Base 1
• CHO Feed Base K
• CHO Feed Base L
• CHO Feed Base M
• CHO Feed Base N

CDACF Version 8 Feeds means the concentrated nutrient solutions used in order to maintain the growth and productivity of mammalian cells as listed
CDACF Version 8 Feeds
CHO
SF76
SF71
SF77
SF54
400 g/L D-glucose

CDACF Version 8 Media means the solutions of nutrients used in mammalian cell culture, as listed
CDACF Version 8 Media
CHO
CM76
CM77
CM78
CM79

CDACF Version 8 System means the CDACF Version 8 Base Powders, CDACF Version 8 Feeds, CDACF Version 8 Media, CDACF Version 8 Know-How and the CDACF Version 8 Supplements used either in combination or individually.

CDACF Version 8 Supplements means the supplement solutions, as listed
CDACF Version 8 Supplements
SPE
LTEM ONE
LTEMTWO
SP6
SP7
SP8
SP9
0.8 g/L Tropolone

Patent Rights (Licensor) means the patents and applications
7932087 – Method of expressing recombinant protein in CHO cells
6593140 – Animal cell culture

Licensor is one of the world’s leading suppliers to the pharmaceutical, biotech and specialty ingredients markets. They focus on preventing and curing illness, by supporting their customers to deliver innovative medicines that help treat or even cure a wide range of diseases, as well as creating a healthier environment.

Field of Use
Field of use is for the treatment of pain associated with degenerative joint disease in cats.

Licensee shall use the System only in the expression of Product by insertion of gene(s) coding for Product(s) into the System, and shall not use, cause the use of or permit to be used the System for any purpose not directly authorized by this Agreement. The CDACF Version 8 System may only be used in conjunction with the System and may not be used in conjunction with any other gene expression system or for any other purpose whatsoever.

IPSCIO Record ID: 286023

License Grant
The Licensor of England grants a right and license to develop, make, have made, use, offer for sale, sell, have sold, import and export Licensed Products for use in the Field in the Territory.  

The license s exclusive or non-exclusive on a patent by patent basis.

License Property
Licensor has a product, known as Cxx-870, which contains a recombinant humanized pegylated Fab’ antibody fragment which binds to TNF alpha, or Tumor Necrosis Factor? alpha.

Licensed Product means any product that contains or comprises an Antibody, or any chemically modified Antibody, which recognizes TNF alpha. For the avoidance of doubt, Licensed Product shall not include non-Antibody inhibitors of TNF alpha.

The patents are titled Multichain Polypeptides or Proteins and Processes for their Production;
Recombinant Antibody; Humanized Antibodies; Protein Expression System;  Process for obtaining Antibodies; Monovalent Antibody Fragments;  and, Biological Products.

Field of Use
Field means the prevention, treatment, diagnosis or control of all diseases or conditions in humans or animals; provided, however, that with respect to CDP-571, the Field shall not include the prevention, treatment, diagnosis or control of any diseases or conditions other than rheumatoid arthritis.

IBD Indication means the prevention, treatment or control of Crohn’s Disease and/or ulcerative colitis in humans and/or animals.

RA Indication means the prevention, treatment or control of rheumatoid arthritis in humans.

IPSCIO Record ID: 256275

License Grant
The Licensor, of England, desires to grant to the Licensee, of Germany, a license on a non-exclusive basis of the right to use the Licensor Licensed Patents for the purpose of researching, developing and commercializing the MT201 Product and other products in respect of he EpCAM target.

For the research license, the Licensor of England grants to the Licensee of Germany a non-exclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to perform research and development activities in the Licensee Research Field.

For the commercialization license, Licensor grants a non-exclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to Exploit Licensed Products in the Licensee Licensed Field.

License Property
Licensor is the owner of rights for certain patents and know-how in the field of Antibody Phage Display.

The know-how includes a Training Manual Antibody Phage Display 2002, and, Licensor mammalian expression lgG vectors.

Licensed Product means the MT201 Product and any other product, substance or formulation arising from the EpCAM Target Program, in each case, the Development, manufacture, importation, use or sale of which would, but for the provisions of this Agreement, infringe one or more Valid Claims under the Licensor Licensed Patents, or utilizes the Licensor Background Know-How.

Field of Use
Licensees Licensed Field means the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the EpCAM Target.

Licensees Research Field means the identification or development of Antibody Products for the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the EpCAM Target.

The excluded field is the discovery, isolation, characterization, research, development, and/pr commercialization of an Antibody useful for the diagnosis, treatment and/or prevention of one or more of the following disease conditions wherein the primary scientific rationale or activity is neuronal and/or glial mechanisms of action of neuroprotection neurodegenerative conditions, diabetic neuropathy, pain, spinal cord injury, multiple sclerosis, and, stroke as a disease of the cerebrovasculature.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.